Citi raised the firm’s price target on Candel Therapeutics (CADL) to $26 from $22 and keeps a Buy rating on the shares. The firm says the Phase 2a data for aglatimagene in lung cancer show a “long survival tail.” Citi increased its probability of success for aglatimagene in lung cancer to 60% from 40%
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CADL:
- CAN-2409’s Emerging Survival Benefit and Biomarker-Driven Immunotherapy Platform Support Buy Rating and $23 Target
- Candel Therapeutics’ aglatimagene shows extended long-term survival in NSCLC
- Candel Therapeutics: Strengthened Balance Sheet and Late‑Stage Pipeline Catalysts Support High‑Risk Buy Rating Despite Dilution
- Candel Therapeutics price target lowered to $22 from $24 at Citi
- Restrictive RTW Purchase Agreement Covenants Threaten Candel Therapeutics’ Financial Flexibility and Increase Default Risk